Dulaglutide
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1147 publications
Endocrinology: What You May Have Missed in 2025.
Journal: Annals of internal medicine
Published: April 13, 2026
Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.
Journal: Annals of internal medicine
Published: March 30, 2026
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
Journal: JAMA cardiology
Published: March 28, 2026
Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.
Journal: European heart journal
Published: March 25, 2026
SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes
Journal: Revue medicale de Liege
Published: March 12, 2026
Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
Journal: JAMA internal medicine
Published: March 02, 2026
GLP-1 and the cardiovascular system.
Journal: The Journal of clinical investigation
Published: February 16, 2026
Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Journal: Healthcare (Basel, Switzerland)
Published: February 10, 2026
A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.
Journal: Journal of clinical medicine
Published: February 04, 2026
Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.
Journal: JAMA network open
Published: January 28, 2026
Last Updated: 04/28/2026